Back to Search
Start Over
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
- Source :
-
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2004 Jun; Vol. 48 (6), pp. 2091-6. - Publication Year :
- 2004
-
Abstract
- The aim of the present study was to assess the pharmacokinetic behavior of atazanavir-ritonavir when it is coadministered with tenofovir disoproxil fumarate (DF) in human immunodeficiency virus (HIV)-infected patients. Eleven patients enrolled in Agence Nationale de Recherche sur le SIDA (National Agency for AIDS Research, Paris, France) trial 107 were included in this pharmacokinetic study. They received atazanavir at 300 mg and ritonavir at 100 mg once a day (QD) from day 1 to the end of study. For the first 2 weeks, their nucleoside analog reverse transcriptase inhibitor (NRTI) treatments remained unchanged. Tenofovir DF was administered QD from day 15 to the end of the study. Ongoing NRTIs were selected according to the reverse transcriptase genotype of the HIV isolates from each patient. The values of the pharmacokinetic parameters for atazanavir and ritonavir were measured before (day 14 [week 2]) and after (day 42 [week 6]) initiation of tenofovir DF and are reported for the 10 patients who completed the study. There was a significant decrease in the area under the concentration-time curve from 0 to 24 h (AUC(0-24)) for atazanavir with the addition of tenofovir DF (AUC(0-24) ratio, 0.75; 90% confidence interval, 0.58 to 0.97; P = 0.05). There was a trend for a decrease in the minimum concentrations of atazanavir and ritonavir in plasma when they were combined with tenofovir, but none of the differences reached statistical significance. The median decreases in the HIV RNA loads at week 2 and week 6 were 0.1 and 0.2 log copies/ml, respectively. In summary, our data are consistent with the existence of a significant interaction between atazanavir and tenofovir DF.
- Subjects :
- Adenine adverse effects
Adenine pharmacokinetics
Adult
Anti-HIV Agents adverse effects
Anti-HIV Agents pharmacokinetics
Antiviral Agents adverse effects
Antiviral Agents pharmacokinetics
Area Under Curve
Atazanavir Sulfate
Chromatography, High Pressure Liquid
Drug Interactions
Female
HIV Infections virology
Humans
Male
Middle Aged
Oligopeptides adverse effects
Oligopeptides pharmacokinetics
Organophosphorus Compounds adverse effects
Organophosphorus Compounds pharmacokinetics
Pyridines adverse effects
Pyridines pharmacokinetics
Ritonavir adverse effects
Ritonavir pharmacokinetics
Spectrophotometry, Ultraviolet
Tenofovir
Adenine analogs & derivatives
Adenine pharmacology
Anti-HIV Agents pharmacology
Antiviral Agents pharmacology
HIV Infections drug therapy
HIV-1
Oligopeptides pharmacology
Organophosphonates
Organophosphorus Compounds pharmacology
Pyridines pharmacology
Ritonavir pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 0066-4804
- Volume :
- 48
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Antimicrobial agents and chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 15155205
- Full Text :
- https://doi.org/10.1128/AAC.48.6.2091-2096.2004